SCHEMBL2570296

SCHEMBL2570296

COc1cc(C=O)ccc1-c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 1/20 0.59
ALDH1A1 P00352 6/20 0.59
TSHR P16473 1/20 0.59
HPGD P15428 2/20 0.54
TRIM24 O15164 1/20 0.54
ALDH5A1 P51649 1/20 0.54
ABAT P80404 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
TRIM33 Q9UPN9 1/20 0.54
FDPS P14324 1/20 0.51
ALDH1A3 P47895 1/20 0.50
AOX1 Q06278 1/20 0.50
CYP2C9 P11712 3/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
MAPT P10636 2/20 0.47
RXFP1 Q9HBX9 1/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3926144 0.86 TTR (0.59) TTRALDH1A1TSHRHPGDTRIM24
SCHEMBL30882827 0.85 ALDH1A1 (0.73) TTRALDH1A1TSHRHPGDTRIM24
SCHEMBL14834816 0.84 ALDH1A1 (0.61) TTRALDH1A1TSHRHPGDTRIM24
SCHEMBL1206443 0.84 ALDH1A1 (0.53) TTRALDH1A1TSHRHPGDTRIM24
SCHEMBL6481230 0.83 ALDH1A1 (0.56) TTRALDH1A1TSHRHPGDTRIM24
SCHEMBL896203 0.83 TRPA1 (0.54) TTRALDH1A1TSHRHPGDTDP1
SCHEMBL10486971 0.83 FDPS (0.51) TTRALDH1A1HPGDTDP1FDPS
SCHEMBL2955584 0.82 ALDH1A1 (0.58) TTRALDH1A1TSHRHPGDTDP1
Biphenyl SCHEMBL17780117 0.80 ALDH1A1 (0.81) TTRALDH1A1TSHRHPGDTRIM24
SCHEMBL20545861 0.80 TUBB4A (0.51) TTRALDH1A1TSHRHPGDTRIM24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4548355-A1 CHEMICAL SYNTHESIS PLATFORM The University Court Of The University Of Glasgow (GB) 2025-05-07 EP disclosed
CN-111948905-B Crosslinking agent, photosensitive resin composition and application thereof 固安鼎材科技有限公司 2025-04-08 CN disclosed
CN-113347979-B Carborane compounds, carborane analogs, and methods of use thereof 俄亥俄州创新基金会 2024-08-16 CN disclosed
WO-2024052692-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-03-14 WO disclosed
CN-117430570-A Rhodamine acetic acid compound, and pharmaceutical composition and application thereof 中国医学科学院药物研究所 2024-01-23 CN disclosed
WO-2024003151-A1 CHEMICAL SYNTHESIS PLATFORM THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) 2024-01-04 WO disclosed
CN-111848954-B Modified polyimide precursor resin, photosensitive resin composition and application thereof 北京鼎材科技有限公司 2023-10-17 CN disclosed
CN-111171317-B Modified polyimide precursor resin, photosensitive resin composition containing same and application of photosensitive resin composition 北京鼎材科技有限公司 2023-04-07 CN disclosed
CN-110194743-B Phenyl (3-methoxy-4- (4-methyl-1H-imidazole-1-yl) phenyl) ketone compound 云南大学 2022-11-11 CN disclosed
CN-114773249-A Compounds, pharmaceutical compositions and methods for treating inflammatory diseases 艾匹克治疗公司 2022-07-22 CN disclosed
US-20070179115-A1 Purinenucleoside derivative modified in 8-position and medical use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1813623-A1 PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2007-08-01 EP disclosed
EP-1698635-A1 BENZIMIDAZOLE DERIVATIVES AND MEDICAL USES THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2006-09-06 EP disclosed
US-6613782-B2 For treating and/or preventing endothelin dependent conditions, e.g. cardio- and cerebro-vascular disorders such as hypertension, vasoconstriction, congestive heart failure, cerebral disorders, respiratory system disorders NOVARTIS AG (CH) 2003-09-02 US disclosed
EP-1317451-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2003-06-11 EP disclosed
US-6423727-B1 Certain thiol inhibitors of endothelin-converting enzyme NOVARTIS AG (CH) 2002-07-23 US disclosed
US-20020082218-A1 Certain thiol inhibitors of endothelin-converting enzyme LOMBAERT STEPHANE DE (US) 2002-06-27 US disclosed
WO-2002034745-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2002-05-02 WO disclosed
EP-1073674-A1 THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME Novartis AG (CH) 2001-02-07 EP disclosed
WO-1999055726-A1 CERTAIN THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME NOVARTIS AG (CH) 1999-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179115-A1 Purinenucleoside derivative modified in 8-position and medical use thereof NUDT1, SLC28A2, PNP TTR 951/4885ALDH1A1 1206/4885TSHR 2798/4885
US-20020082218-A1 Certain thiol inhibitors of endothelin-converting enzyme ECE1, ECE2, EDNRB TTR 162/4885ALDH1A1 139/4885TSHR 2106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.